Google develops AI to predict medical outcomes

Cara Livernois | | Health Exec | Artificial Intelligence

Artificial intelligence (AI) researchers at Google have developed an AI system capable of predicting patient’s medical outcomes once admitted to the hospital.

The AI, which was developed using three deep neural networks, was trained on electonic health record data from 216,221 adult patients. According to the recent study, the AI analyzed more than 46 million data points covering 11 years from University of California, San Francisco Medical Center (from 2012-2016) and University of Chicago Medicine (2009-2016).

Perhaps most notable is the claim that the AI can predict patient death 24 to 48 hours before current methods.

Read the full story below:

Google is using 46 billion data points to predict the medical outcomes of hospi…

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Advancing AI for vascular surgery will require a commitment to data integrity
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
New AI program delivers rapid, accurate echo video assessments
ICU diary-keeping: There’s an AI for that
FDA commissioner urges health systems to strengthen AI quality oversight

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.